Discovering new antimicrobial agents (Q37809382)

23 August 2017

title

Discovering new antimicrobial agents (English)

1 reference

23 August 2017

Robert C. Moellering

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21075608

26 August 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21075608

26 August 2024

publication date

13 November 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0924857910004073?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

https://api.elsevier.com/content/article/PII:S0924857910004073?httpAccept=text/plain

26 August 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

International Journal of Antimicrobial Agents

26 August 2024

published in

1 reference

23 August 2017

volume

37

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

2-9

1 reference

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.

26 August 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Drugs for bad bugs: confronting the challenges of antibacterial discovery

26 August 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

The business of developing antibacterials

26 August 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Tackling antibiotic resistance

26 August 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Shifting goalposts in antibiotic approval

26 August 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Future antibiotics scenarios: is the tide starting to turn?

26 August 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model

26 August 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus

26 August 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

New insights into the mechanism of action of lantibiotics--diverse biological effects by binding to the same molecular target

26 August 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

26 August 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

In vitro activity of ceftobiprole against Gram-positive and Gram-negative bacteria isolated from humans and animals

26 August 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States

26 August 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance

26 August 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Molecular Characterization of Off-Target Activities of Telithromycin: a Potential Role for Nicotinic Acetylcholine Receptors

26 August 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Telavancin: a novel lipoglycopeptide

26 August 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Mechanism of action of oritavancin and related glycopeptide antibiotics

26 August 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala.

26 August 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.

26 August 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia

26 August 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic

26 August 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.

26 August 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia

26 August 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms

26 August 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent

26 August 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli

26 August 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Iron-regulated outer membrane proteins of Escherichia coli K-12 and mechanism of action of catechol-substituted cephalosporins

26 August 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Mode of action of GR69153, a novel catechol-substituted cephalosporin, and its interaction with the tonB-dependent iron transport system

26 August 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Rationale for use of antimicrobial combinations

26 August 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Can the third-generation cephalosporins eliminate the need for antimicrobial combinations?

26 August 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy

26 August 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Three decades of beta-lactamase inhibitors

26 August 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor

26 August 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Mechanisms of action of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines in Escherichia coli

26 August 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound

26 August 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Systematic approach to optimizing specifically targeted antimicrobial peptides against Streptococcus mutans

26 August 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

26 August 2024

Peptide antibiotics.

38

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.

26 August 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein

26 August 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group

26 August 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms

26 August 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Nontoxic membrane-active antimicrobial arylamide oligomers.

26 August 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Effects of hydrophobicity on the antifungal activity of alpha-helical antimicrobial peptides

26 August 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Role of peptide hydrophobicity in the mechanism of action of alpha-helical antimicrobial peptides

26 August 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa

26 August 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

NB-002, a novel nanoemulsion with broad antifungal activity against dermatophytes, other filamentous fungi, and Candida albicans

26 August 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species

26 August 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus

26 August 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Quorum sensing: a novel target for anti-infective therapy

26 August 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Two-component signal transduction as a target for microbial anti-infective therapy

26 August 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis

26 August 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Discovery of a novel and potent class of FabI-directed antibacterial agents

26 August 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds

26 August 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors

26 August 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity

26 August 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

RNA Second Messengers and Riboswitches: Relics from the RNA World?

26 August 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Antibacterial lysine analogs that target lysine riboswitches

26 August 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections

26 August 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Reinventing phage therapy: are the parts greater than the sum?

26 August 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus

26 August 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.08.018

26 August 2024

Identifiers

1 reference

23 August 2017

1 reference